Kyowa Hakko Bio succeeded its bio-chemical business from Kyowa Hakko Kogyo and was established in 2008. Kyowa Hakko Kogyo can thus be regarded as the predecessor of Kyowa Hakko Bio.
Kyowa Hakko Kogyo
|1949||Establishment of Kyowa Hakko Kogyo.|
|1951||Introduced production technology of Streptomycin, an anti-tubercular drug from US pharmaceutical company Merck & Co. Inc., and succeeded in its mass production.|
|1956||Succeeded in the isolation and commercial mass-production of the anticancer drug MitomycinC.
World's first invention of the process of L-Glutamic acid production by fermentation. Pioneered in the major business industry of amino-acid fermentation.
|1958||Invention of the process of L-Lysine production by fermentation.
Release of a plant growth regulator Gibberellin Kyowa (contributed to production of seedless grapes).
|1969||Establishment of Kyowa Hakko USA.|
|1973||Establishment of Kyowa Hakko Europe.|
|1981||Establishment of the Bio Business Headquarters.|
|2005||Completion of the transition to an operating holding company (Pharmaceuticals and Bio-chemicals are its main pillars).|
|2007||Announcement of a strategic alliance between Kyowa Hakko Group and Kirin Group.|
Kyowa Hakko Bio
|2008||Establishment of Kyowa Hakko Bio
(succeeded Bio-Chemical business from Kyowa Hakko Kogyo).
Announcement of a strategic alliance between Kyowa Hakko Group and Kirin Group.
|2015||Completion of Construction for Amino Acid Manufacturing Plant in Thailand|
|2019||Became a direct subsidiary of Kirin Holdings
Company, Limited through transfer of shares